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S U M M A R Y
High-throughput techniques strive to identify new biomarkers that will be useful for the diagnosis,
treatment, and prevention of tuberculosis (TB). However, their analysis and interpretation pose
considerable challenges. Recent developments in the high-throughput detection of host biomarkers in
TB are reported in this review.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
There is a widely acknowledged need for novel biomarkers of
tuberculosis (TB), for all levels of TB diagnosis, treatment, and
prevention.1–3 Much effort in this direction has been devoted to
host biomarkers, because progression towards clinical disease can
be detected by specific changes that are evoked by the pathological
processes in the host organism. In TB, this is a particular advantage,
as the diagnosis of direct symptoms of TB (e.g., by [10_TD$DIFF]auscultation or
chest X-ray (CXR), through detection of the causative agent, acid-
fast bacteria in sputum by microscopy, or positive bacterial
cultures) [11_TD$DIFF] may sometimes be problematic. Sputum samples are
difficult to obtain from neonates, who moreover frequently suffer
from extrapulmonary TB.
However, there are further reasons to focus on the host
response. The onset of active TB disease is frequently delayed for
years, and the time span between the first TB symptoms and
diagnosis has been estimated to range from 5 days to as long as
162 days.4 [1_TD$DIFF] Thus, TB may exist without apparent symptoms,
although the molecular processes underlying TB pathology have
already commenced. Likewise, TBmay persist in a subclinical stage
after drug treatment and may later relapse. Positron emission
computed tomography (PET/CT) has revealed hallmarks of active
TB in patients who have been treated successfully.5 Host* Corresponding author.
E-mail address: january@mpiib-berlin.mpg.de (J. Weiner).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).biomarkers may provide a sensitive and specific approach to
detect subclinical manifestations of clinical or subclinical TB.
The early detection of TB is another important area for
biomarker research. Of two billion Mycobacterium tuberculosis-
infected individuals, most remain healthy but infected (latent TB
infection, LTBI) and only a fraction of 5–7% will develop clinical TB
during their lifetime. Although M. tuberculosis infection can be
determined reliably by interferon gamma release assay (IGRA), this
test cannot be used to diagnose or determine the prognosis of
active TB.6 Thus, the identification of biomarkers of TB risk and
early stage of progression to active TB would allow screening for
individuals at risk. This would allow preventive drug therapy, and
also interruption of transmission, with a marked influence on
treatment success. Practically, the treatment outcome cannot be
assessed in a point-of-care setting. Although PET/CT has predictive
value for the treatment outcome,7 [2_TD$DIFF] simpler and more accessible
tests have thus far failed. For example, although CXR allows a
reliable diagnosis of TB, it has limited predictive value for the
treatment outcome.8 Early and personalized treatment adjust-
ment, as well as prediction of the treatment outcome in new drug
trials is a major concern in the face of increasing incidences of
drug-resistant TB.
2. Computational approaches to high-throughput biomarkers
High-throughput techniques such as transcriptomics allow the
inspection of tens of thousands of variables (such as gene
expression, protein or metabolite levels) in one step (A glossaryciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Glossary
Biomarker A measurable indicator of the organism state.
Signature A set of individual biomarkers, corresponding values, and specific machine learningmodels, which act together as an indicator of the
state of an organism.
Predictive vs. prospective Biomarkers that allow the prediction of the likely natural course of the untreated disease in the individual are termed ‘prospective
biomarkers’. Biomarkers that allow the prediction of the outcome of treatment are termed ‘predictive biomarkers’.
Machine learning (ML) Methods in computer science that allow the construction of a model of reality based on automatic inspection of data. In ‘supervised
ML’, a model of reality is first derived from a training data set, and subsequently validated by application to a test data set. For
example, a model can be trained on gene expression data from TB patients and healthy controls. Its performance will then be
evaluated by applying the model to a separate validation set.
ROC curve A curve describing the predictive ability of a supervised ML model, showing all possible combinations of specificity and sensitivity
that can be obtained from that model[9_TD$DIFF].
Random forests A type of supervisedML inwhich a large number of partially randomized decision trees is generated. When applied to a sample, each
tree casts a vote, and the model then decides on the classification of the sample by majority rule.
Variable importance A measure that determines the relative importance of different variables for correctly classifying a sample by a machine learning
model.
Gene set enrichment analysis Genes (or other variables) can be grouped into functional categories such as gene ontology sets, co-expression modules, or sets of
genes that are up- or down-regulated in a particular condition or are specific for a given cell subtype. Gene set enrichment analysis
can take advantage of such a classification by testing whether a particular category of genes (e.g., interferon inducible genes or
monocyte surface proteins) are enriched in genes that are strongly regulated in a given comparison (e.g., TB vs. healthy controls).
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large number of variables (compared to the number of samples
analysed) is a two-edged sword. The obvious advantage of such an
approach is the comparatively unbiased acquisition of a large
number of potential candidates. On the other hand, if the number
of variables is much larger than the number of samples utilized,
sophisticated and careful statistical analyses are necessary. Most
importantly, the statistical power for detecting a single or a few
suitable biomarkers amongst the thousands of variables analysed
decreases profoundly, thus correct signals are often hidden in a
deluge of false-positives. Moreover, given that the number of
functionally characterized protein-coding genes remains insuffi-
cient, and only a few microRNAs have been functionally
characterized, the interpretation of results may pose an additional
obstacle.
[3_TD$DIFF] ata mining tools such as supervised and unsupervised
learning have been employed successfully in a number of
biomarker studies.2,9 [12_TD$DIFF] Supervised machine learning algorithms
include both established methods (such as linear discrimination
analysis,10 k-nearest neighbour algorithm,11 and random for-
ests12,13) and novel, unique approaches. Zak et al.14 constructed a
new classification method by combining k-top-scoring pairs15
with support vector machines (SVMs), taking advantage of
relatively simple interpretability of the k-top-scoring pairs
approach with the flexibility of SVMs. Kaforou et al. defined a
new metrics termed the ‘disease risk score’ (DSR), defined as the
sum of signed absolute intensities of discriminatory biomarkers,
combined with a TB/no TB threshold.16 Despite the computational
simplicity of DSR, it was shown to perform well in discriminating
TB patients both from healthy individuals and from patients
suffering from other diseases.
A disease signature is only superficially a compilation of
variables (e.g., genes) that differ between two conditions. Firstly, as
a minimum these variables are linked to particular values (e.g.,
gene expression in healthy individuals and in TB patients, as in the
k-nearest neighbour algorithm) or more complex structures (e.g.,
decision trees). Secondly, most machine learning algorithms
provide a score, which subsequently is compared to an arbitrarily
chosen threshold. This latter step, however, depends on a given
context, because modifying the threshold optimizes either
specificity or sensitivity. As a solution, results of such biomarker
analyses are frequently shown as so-called receiver operating
characteristic (ROC) curves—all possible sensitivity/specificity
combinations for a given signature (Figure 1A).
The interpretation of signatures is increasingly confounded by
the size and complexity of themodel. While biological functions towhich a four-gene signature is related may be glimpsed with
relative ease, it is much harder to gain an overview in more
complex cases. However, machine learning algorithms often allow
the calculation of a ‘variable importance’ (VI) measure. VI can be
used to rank genes according to their contribution to the model,
which in turn can be used by adapting a gene set enrichment
analysis framework such as GSEA21 [13_TD$DIFF], piano,22 [14_TD$DIFF] or tmod.20 [8_TD$DIFF] In the case
of a [15_TD$DIFF]shrunken model based on a subset of genes, the subset itself
can be tested for enrichment in relevant classes of genes.
Note that all statistical approaches are based on assumptions,
which incompletely fit the biological reality. Moreover, the large
number of variables tested in a high-throughput setting increases
the risk of false-positives, evenwhen strictly adhering to standards
in statistical methodology, e.g. by using a suitable method for
family-wise error correction. It has been estimated that at p < 0.05,
as many as 30% of the rejected hypotheses may be false-
positives,23 irrespective of using a correction for multiple testing,
which may be one of the reasons for the much debated
‘reproducibility crisis’ in science. The point here is that high-
throughput analyses are especially vulnerable to these problems.
Three not mutually exclusive approaches are suggested here,
which do not require additional statistical assumptions or novel
techniques. Firstly, because unblinded studies overestimate the
actual observed effect size,24 [16_TD$DIFF] any biomarker study in future should
consider separating (‘locking’) a randomly chosen subset of
samples for a blinded, post-hoc validation of the findings, and
studies should be evaluated by adherence to this rule. Secondly, an
independent analysis by several statisticians (both as study
authors and reviewers) would greatly increase confidence in the
findings. Thirdly, biomarker studies need to be validated in various
settings and cohorts, and using independent experimental
approaches. This would facilitate the process of translating the
high-throughput to practical clinical applications.
3. High-throughput biomarkers in TB
3.1. Transcriptomic profiling
High-throughput-derived transcriptomic biomarkers have
been studied for almost a decade in TB, with the first studies
appearing in 2007.2,10,25 The broadly studied differences in gene
expression between TB patients and healthy (infected or uninfect-
ed) controls thus far have been investigated in a total of over a
thousand individuals on four continents. Kaforou et al. included
over 500 individuals in two cohorts, not only TB patients and
healthy controls (both HIV-negative and HIV-positive), but also
[(Figure_1)TD$FIG]
Figure 1. Classification results of random forest training for transcriptomic samples from TB patients compared to healthy controls. (A) Receiver operating characteristic
(ROC) curves showing the relative performance of the transcriptomic signatures in distinguishing between the two groups. (B) Results of the gene set enrichment analysis as
applied to genes, sorted by their importance in the random forest models. The size of the points indicates the effect size of the gene set enrichment (AUC), and bolder colours
are used for lower q-values. The transcriptomic profiles were derived from five independent studies11,16,17– [7_TD$DIFF]19[6_TD$DIFF] and the enrichment was calculated using the tmod package.20 [8_TD$DIFF]
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clinically diagnosedwith other diseases.16 The biomarkers identified
include components of the interferon gamma response (such as
CD64, identified by Jacobsen et al.25), neutrophil-driven interferon
signature,11,17,19[17_TD$DIFF] down-regulation of T-cell- and B-cell-related genes,
and others.26,27 These initial signatures were defined as sets of
differentially regulated genes characteristic of gene expression in the
blood of TB patients and involved up to several hundred genes.
Despite the universality of qualitative findings, the balance in the
extent of regulation found to occur in different areas of the host
response may differ between the studies. For example, random
forestmodels based on data derived fromBerry et al.11[18_TD$DIFF] showa strong
interferon response dominating the signature (in concordance with
the main conclusions of the authors), while the data from Kaforou
et al.16 are dominated by changes in expression of T-cell- and B-cell-
related genes (see Figure 1B). It is difficult to decide by purely
computational criteria whether these shifts in the different parts of
the immune system may be due to different technical platforms or
whether they reflect real biological differences.
Meta-analyses combined with a rigorous variable selection
process allow the size of transcriptomic biosignatures to be
reduced to as few as three or four genes (Maertzdorf et al.;13
Sweeney et al.28 [19_TD$DIFF]). In fact, a concise ([15_TD$DIFF]shrunken) four-gene signature
based on comparison between healthy controls and TB patients
turned out to be more specific for TB than larger signatures
involving 15 or more genes, and even allowed the discrimination
between TB and other pulmonary diseases when applied to
independent data sets and cohorts.13 It is possible that a broader
signature involves genes that capture the general aspects of TB
disease (such as inflammation or other unspecific innate
responses) shared with other diseases. Note that these concise
transcriptomic signatures are remarkably universal, and the
models built can be successfully validated on data sets derived
from other cohorts and technical platforms used to obtain the data.Recently, transcriptomic profiling has been applied in a
longitudinal studywith the goal of obtaining a predictive signature
for active TB disease. Zak and colleagues followed healthy
adolescents from South Africa for 2 years, collecting blood samples
every 6 months.14 Out of several thousand study participants,
46 individuals were eventually diagnosed with TB. Transcriptomic
profiles were obtained from blood samples of these individuals,
collected prior to the time point of TB diagnosis, and were
compared to profiles of those individuals who remained healthy
throughout the study. Indeed, these profiles (which were all
collected from apparently healthy individuals) were able to
discriminate between the two groups in the study design, with
statistical significance, even though the statistical performance (as
it was to be expected) was not comparable to the power of
transcriptomic profiles in discriminating between healthy individ-
uals and TB patients. The results of the study have been confirmed
using an independent set of samples obtained from another
longitudinal cohort collected in the Grand Challenges GC6-74
effort.29 [20_TD$DIFF]
There were two further notable findings in this study. Firstly,
the biomarkers identified largely coincided with the biomarkers
for clinical TB diagnosis, including CD64 (identified by Jacobsen
et al.25) and several interferon inducible genes.11 In other words,
the prognostic or predictive signature of TB obtained overlaps with
the diagnostic signature of clinical TB. Secondly, there was a clear
time dependence relative to time point of clinical diagnosis:
samples obtained within the 12 to 18 months prior to clinical
diagnosis produced a predictive signature, but samples obtained
earlier did not. These findings suggest that the biomarkers
identified do not correspond to a persistent TB risk (or, reciprocally,
an inherent protectivity), but more likely are indicative of an
incipient, subclinical form of TB. This is in line with recent findings
that apparently healthy individuals after successful drug treat-
ment show an ongoing TB process that can be captured with PET.5
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cohorts.
The elephant in the roomwhen it comes to blood transcriptome
studies is the fact that it is generally impossible to reliably
distinguish between bona fide gene regulation within a cell and
changes or differences in the composition of the cell populations
constituting the analysed samples. While differential cell counts
sometimes accompany blood transcriptomic data, this is likely
insufficient if, for example, the observed effects are due to changes
in the migration pattern of T lymphocytes or specific subtypes
thereof. Future analyses involving single-cell RNA sequencing
(scRNASeq) may shed further light on fine differences in the state
of the individual cells and cell compositions of the investigated
tissue.
3.2. Further high-throughput approaches
Transcriptomic analyses have been followed by large-scale
proteomic analyses. De Groote et al. used a highly multiplexed
proteomics approach to analyse serum from TB patients before and
after treatment and identified a number of potential biomarkers,
including C-reactive protein, the metallopeptidase inhibitor
TIMP2, thrombospondin 4 (THBS4), and serum amyloid A (SAA),
as well as a number of involved pathways, including microbial
pattern recognition, coagulation and complement system, as well
as, to lesser extent, the interferon gamma pathway.30 [21_TD$DIFF] Similar
results were obtained in a large-scale comparison of serum protein
biomarkers from TB patients and healthy controls.31 [22_TD$DIFF]
Several studies have analysed the differences in microRNA
profiles between TB patients and healthy controls, both in RNA
extracted from peripheral blood cells18,32– [24_TD$DIFF]35 [23_TD$DIFF] and freely circulating
microRNAs found in patient serum or plasma samples.36–[26_TD$DIFF]38 [25_TD$DIFF]
However, our incomplete knowledge about microRNA functions
makes it hard to reliably interpret mere lists of identifiers in terms
of biological functionality. In-depth computational and experi-
mental assessment of candidate biomarkers shows that micro-
RNAs can play an important role in regulating the immune
response,39 [27_TD$DIFF] for example by influencing the recruitment of
neutrophils to the lung.34 [28_TD$DIFF]
Metabolic profiling of serummetabolites bymass spectrometry
has demonstrated excellent performance in discriminating TB
patients from healthy controls.12 The analyses revealed changes in
lysophosphatidylcholines, amino acids (notably glutamine and
glutamate), bile acids, and fibrinopeptides, and the top biomarkers
included inosine, cortisol, and kynurenine. Kynurenine is known to
correlate with increased expression of indoleamine 2,3-dioxygen-
ase upon contact withM. tuberculosis, while adenosine deaminase,
which enzymatically converts adenosine to inosine, has been
identified as a potential serum proteomic biomarker for TB.40 [29_TD$DIFF] Zhou
et al. confirmed some of these findings in a nuclear magnetic
resonance (NMR) rather than mass spectrometry based
approach.41 [30_TD$DIFF] Another study also showed changes in metabolic
profiles upon TB drug treatment; however, the study design did not
allow for an unambiguous annotation of the unique molecular
features collected.42 [31_TD$DIFF] Frediani et al. identified metabolites in the
plasma samples of 17 TB patients and found, in addition to some of
the previous findings, a higher abundance of resolvins and
compounds that may directly be derived from M. tuberculosis cell
wall lysis.43 [32_TD$DIFF]
Few investigators have considered epigenetic modifications as
potential TB biomarkers. Esterhuyse et al. simultaneously collected
DNA methylation data, transcriptomic profiles (including micro-
RNAs), and proteomic profiles from monocytes and neutrophils
isolated from TB patients and healthy controls.39 [27_TD$DIFF]
At the bottom line, these studies demonstrate that the deep
impact of TB on the host can reliably be acquired by high-throughput techniques at all levels tested to date. Significant
changes in TB can be observed for virtually any tissue andmolecule
type tested. Universal, but TB-specific patterns emerge, including
the interferon response or changes in host metabolism. In spite of
this, the data are both too rich and too poor.
Firstly, studies comparing TB to healthy controls are abundant
and have generated a diverse landscape of data sets. Meta-analyses
(such as the one performed on transcriptomic data by Joosten
et al.26 and that by Sweeney et al.28 [19_TD$DIFF]) are now a key task for
computational analyses. Unfortunately, while primary transcrip-
tomic readouts (i.e., signal intensities for microarrays or read
counts for RNASeq) are usually readily available from the GEO
database, other types of data are less frequently disclosed upon
publication.
On the other hand, most of the aforementioned study designs
have primarily considered the comparison between TB patients
and healthy controls or TB patients before and after treatment.
Although transcriptomic profiling demonstrates that even signa-
tures derived purely from such designs can be used to reliably
discriminate between TB and other diseases with similar
symptoms,13 the inclusion of patients with other diseases in the
study design of metabolic, epigenetic, and proteomic profiling is a
necessary next step.
4. Outlook
High-throughput techniques such as transcriptomics have
demonstrated their ability to not only distinguish TB patients
from healthy individuals, but also to discriminate between TB and
other diseases, monitoring treatment outcome and even predicting
the onset of active TB months before a clinical diagnosis can be
performed. Although current biosignatures are composed of
dozens, if not hundreds of variables, first attempts to reduce the
number of transcripts in transcriptomic profiling of TB show that
not only is the information contained in such large biosignatures
redundant, but that more specific signatures can be derived by a
more selective approach.13
Biomarkers in TB are by nomeans limited to the transcriptome,
and several studies have shown that TBmanifests itself on different
levels. Given that even within blood, transcriptomic profiles
(derived only from peripheral blood cells) are not necessarily fully
correlated to profiles of serummolecules (derived from other cells
as well as peripheral blood cells), combining biomarkers from
these different platforms may improve the overall performance of
biosignatures.
Most importantly, new, independent studies in different
cohorts are needed to allow for meta-analyses and the construc-
tion of concise, universal, and predictive TB biosignatures.
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